Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Journal of Clinical Oncology, Vol 26, No 3 (January 20), 2008: pp. 463-467
© 2008 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2007.13.0344

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lara, P. N.
Right arrow Articles by Gandara, D. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lara, P. N., Jr
Right arrow Articles by Gandara, D. R.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Disease Control Rate at 8 Weeks Predicts Clinical Benefit in Advanced Non–Small-Cell Lung Cancer: Results From Southwest Oncology Group Randomized Trials

Primo N. Lara, Jr, Mary W. Redman, Karen Kelly, Martin J. Edelman, Stephen K. Williamson, John J. Crowley, David R. Gandara

From the University of California Davis Cancer Center, Sacramento, CA; Fred Hutchinson Cancer Research Center, Seattle, WA; Cancer Research and Biostatistics, Seattle, WA; University of Colorado, Denver, CO; University of Maryland, Baltimore, MD; and the University of Kansas, Kansas City, KS

Corresponding author: Primo N. Lara Jr, MD, University of California Davis Cancer Center, 4501 X St, Sacramento, CA 95817; e-mail: primo.lara{at}ucdmc.ucdavis.edu

Purpose Tumor shrinkage categorized as complete response (CR) or partial response (PR) is a fundamental efficacy measure for new cancer treatments and often considered a surrogate for overall survival. However, for any given treatment, many more patients typically achieve stable disease (SD) or have progressive disease (PD) than achieve response. We hypothesized that PD (or its converse, disease control rate [DCR], consisting of CR, PR, SD) is a stronger predictor of survival than response alone in advanced non–small-cell lung cancer (NSCLC), and that this determination might be assessable early on during therapy.

Patients and Methods Data from 984 NSCLC patients entered onto three randomized Southwest Oncology Group trials of platinum-based chemotherapy were pooled and subjected to Landmark survival analysis. Patients were categorized according to proportions alive at weeks 8, 14, and 20 after registration, as well as response status. Elements were fitted into a Cox proportional hazards model.

Results Tumor response (CR, PR) was seen in 260 patients (27%). Median time to response, time to progression, and survival time were 2.0, 4.3 and 8.9 months, respectively. Median survival times among patients with CR/PR, SD, or PD were 13.5, 8.4, and 3.1 months, respectively. Of 892 patients alive at week 8, DCR was 62%. Although CR/PR at week 8 was associated with longer survival (hazard ratio [HR] = 0.61; P < .001), DCR was superior in predicting survival (HR = 0.45; P < .0001).

Conclusion DCR at week 8 is a more powerful predictor of subsequent survival than is the traditional tumor response rate in advanced NSCLC and provides an early assessment of subsequent outcome.

Presented in part at the 42nd Annual Meeting of the American Society of Clinical Oncology, June 2-6, 2006, Atlanta, GA.

Authors’ disclosures of potential conflicts of interest and author contributions are found at the end of this article.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
JCOHome page
C. M. Booth, P. Ohorodnyk, and E. A. Eisenhauer
Call for Clarity in the Reporting of Benefit Associated With Anticancer Therapies
J. Clin. Oncol., November 20, 2009; 27(33): e213 - e214.
[Full Text] [PDF]


Home page
JCOHome page
T. S.K. Mok, Y.-L. Wu, C.-J. Yu, C. Zhou, Y.-M. Chen, L. Zhang, J. Ignacio, M. Liao, V. Srimuninnimit, M. J. Boyer, et al.
Randomized, Placebo-Controlled, Phase II Study of Sequential Erlotinib and Chemotherapy As First-Line Treatment for Advanced Non-Small-Cell Lung Cancer
J. Clin. Oncol., October 20, 2009; 27(30): 5080 - 5087.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
L. Claret, P. Girard, P. M. Hoff, E. Van Cutsem, K. P. Zuideveld, K. Jorga, J. Fagerberg, and R. Bruno
Model-Based Prediction of Phase III Overall Survival in Colorectal Cancer on the Basis of Phase II Tumor Dynamics
J. Clin. Oncol., September 1, 2009; 27(25): 4103 - 4108.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
W. J. Gradishar, D. Krasnojon, S. Cheporov, A. N. Makhson, G. M. Manikhas, A. Clawson, and P. Bhar
Significantly Longer Progression-Free Survival With nab-Paclitaxel Compared With Docetaxel As First-Line Therapy for Metastatic Breast Cancer
J. Clin. Oncol., August 1, 2009; 27(22): 3611 - 3619.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
W. A. Weber
Assessing Tumor Response to Therapy
J. Nucl. Med., May 1, 2009; 50(Suppl_1): 1S - 10S.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
F. Grossi, M. Aita, C. Defferrari, F. Rosetti, A. Brianti, G. Fasola, O. Vinante, P. Pronzato, and G. Pappagallo
Impact of Third-Generation Drugs on the Activity of First-Line Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Meta-Analytical Approach
Oncologist, May 1, 2009; 14(5): 497 - 510.
[Abstract] [Full Text] [PDF]


Home page
Am Soc Clin Oncol Ed BookHome page
W. A. Weber
The Use of Positron Emission Tomography versus Computerized Tomography Scans in the Assessment of Response to Therapy
ASCO Educational Book, January 1, 2009; 2009(1): 474 - 478.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
K. Yonesaka, K. Zejnullahu, N. Lindeman, A. J. Homes, D. M. Jackman, F. Zhao, A. M. Rogers, B. E. Johnson, and P. A. Janne
Autocrine Production of Amphiregulin Predicts Sensitivity to Both Gefitinib and Cetuximab in EGFR Wild-type Cancers
Clin. Cancer Res., November 1, 2008; 14(21): 6963 - 6973.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
T. Tanvetyanon, E. A. Eikman, E. Sommers, L. Robinson, D. Boulware, and G. Bepler
Computed Tomography Response, But Not Positron Emission Tomography Scan Response, Predicts Survival After Neoadjuvant Chemotherapy for Resectable Non-Small-Cell Lung Cancer
J. Clin. Oncol., October 1, 2008; 26(28): 4610 - 4616.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
J. R. Anderson, K. C. Cain, and R. D. Gelber
Analysis of Survival by Tumor Response and Other Comparisons of Time-to-Event by Outcome Variables
J. Clin. Oncol., August 20, 2008; 26(24): 3913 - 3915.
[Full Text] [PDF]


Home page
JCOHome page
M. R. Green
Lessons From a Time Capsule: Evolution, Not Revolution, in Therapy for Advanced Non-Small-Cell Lung Cancer
J. Clin. Oncol., July 1, 2008; 26(19): 3112 - 3113.
[Full Text] [PDF]


Home page
Clin TrialsHome page
Xian Zhou, Suyu Liu, E. S Kim, R. S Herbst, and J J. Lee
Bayesian adaptive design for targeted therapy development in lung cancer -- a step toward personalized medicine
Clinical Trials, June 1, 2008; 5(3): 181 - 193.
[Abstract] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2008 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online